Next Article in Journal
The Bright and Dark Sides of Herbal Infusions: Assessment of Antioxidant Capacity and Determination of Tropane Alkaloids
Previous Article in Journal
Metagenome Analysis Identifies Microbial Shifts upon Deoxynivalenol Exposure and Post-Exposure Recovery in the Mouse Gut
Previous Article in Special Issue
Cytoprotective, Antiproliferative, and Anti-Oxidant Potential of the Hydroethanolic Extract of Fridericia chica Leaves on Human Cancer Cell Lines Exposed to α- and β-Zearalenol
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Toxins
Volume 15
Issue 4
10.3390/toxins15040244
toxins-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Patulin Alters Insulin Signaling and Metabolic Flexibility in HepG2 and HEK293 Cells

by
Yashodani Pillay
*,
Savania Nagiah
† and
Anil Chuturgoon
*
Discipline of Medical Biochemistry and Chemical Pathology, Faculty of Health Sciences, George Campbell Building, Howard College, University of KwaZulu-Natal, Durban 4041, South Africa
*
Authors to whom correspondence should be addressed.
†
Current address: Department of Human Biology, Medical School, Nelson Mandela University, Port Elizabeth 6019, South Africa.
Toxins 2023, 15(4), 244; https://doi.org/10.3390/toxins15040244
Submission received: 27 February 2023 / Revised: 22 March 2023 / Accepted: 25 March 2023 / Published: 27 March 2023
(This article belongs to the Special Issue Mechanism of Action of Mycotoxins)
Browse Figures
Versions Notes

Abstract

:
Non-communicable diseases (NCDs) have risen rapidly worldwide, sparking interest in causative agents and pathways. Patulin (PAT), a xenobiotic found in fruit products contaminated by molds, is postulated to be diabetogenic in animals, but little is known about these effects in humans. This study examined the effects of PAT on the insulin signaling pathway and the pyruvate dehydrogenase complex (PDH). HEK293 and HepG2 cells were exposed to normal (5 mM) or high (25 mM) glucose levels, insulin (1.7 nM) and PAT (0.2 μM; 2.0 μM) for 24 h. The qPCR determined gene expression of key enzymes involved in carbohydrate metabolism while Western blotting assessed the effects of PAT on the insulin signaling pathway and Pyruvate Dehydrogenase (PDH) axis. Under hyperglycemic conditions, PAT stimulated glucose production pathways, caused defects in the insulin signaling pathway and impaired PDH activity. These trends under hyperglycemic conditions remained consistent in the presence of insulin. These findings are of importance, given that PAT is ingested with fruit and fruit products. Results suggest PAT exposure may be an initiating event in insulin resistance, alluding to an etiological role in the pathogenesis of type 2 diabetes and disorders of metabolism. This highlights the importance of both diet and food quality in addressing the causes of NCDs.
Keywords:
insulin resistance; kidney; liver; metabolic flexibility; patulin
Key Contribution: The key finding in this study is that exposure to patulin impairs insulin signaling under hyperglycemic conditions and alters metabolic flexibility after 24 h exposure in an in vitro model. This finding was consistent following insulin stimulation; suggestive of an insulin-resistant mechanism.

1. Introduction

Non-communicable diseases (NCDs), including diabetes and cancer, have quickly become the leading cause of mortality worldwide, with disproportionately higher impacts on public health in developing countries [1]. This has raised interest in causative agents, diet and nutritional guidelines. Mycotoxins are secondary metabolites produced by fungi. These potentially damaging xenobiotics are found in food, with a higher incidence in developing countries [2,3].
Patulin (PAT) is a mycotoxin produced by Penicillium, Bissochlamys and Aspergillus sp. [4]. These molds are found in overripe or rotting fruit and apple products. A safety level of 50 μg/L PAT in consumables was established following evidence of adverse effects in exposed humans and animals [3,5]. Despite this regulation and the assertion that PAT levels are a measure of poor product quality, there are vast variations in PAT concentrations in apple products worldwide [5]. PAT induces oxidative stress, compromises mitochondrial function and causes cell death via depletion of antioxidant glutathione (GSH) [6,7,8,9,10,11]. PAT is also associated with changes in lipid metabolism and inflammation [2,12]. These deleterious effects are most commonly observed in organs of high metabolic demand—the kidney, gastrointestinal tract, liver and brain [3,13].
Energy demand and glucose homeostasis are typically maintained through the catabolism of glucose to pyruvate during glycolysis. Pyruvate is subsequently taken up by the mitochondria and broken down in the citric acid (TCA) cycle; subsequently, this facilitates the transfer of electrons to the mitochondrial respiratory chain for ATP production via oxidative phosphorylation. Under hypoxic and hypoglycemic conditions, however, these processes are impaired. These conditions divert metabolic operations to produce glucose through gluconeogenesis and glycogenolysis, resulting in ATP production via anaerobic glycolysis [14]. This metabolic environment is potentially simulated by PAT exposure which has been linked to glycogen breakdown, gluconeogenesis, impaired mitochondrial function and ATP levels in previous studies [15].
Metabolic flexibility is determined by an organism’s ability to adapt fuel oxidation processes to nutrient availability and rapidly switch between them. Pyruvate Dehydrogenase (PDH), a multienzyme complex stimulated by insulin catalyzes the conversion of pyruvate to acetyl-CoA, connecting the TCA cycle to glucose and fatty acid metabolism. PDH activity is thus a central component of metabolic flexibility. The pyruvate dehydrogenase kinases (PDKs) inhibit PDH activity through phosphorylation on the PDH E1α subunit under hypoglycemic and hypoxic conditions. PDK elevation is hence associated with gluconeogenesis, metabolic inflexibility and has been implicated in the etiology of type 2 diabetes [16,17].
Glucose uptake in mammalian cells is facilitated by a family of glucose transporters (GLUTs). GLUT2, expressed in the intestine, liver, kidney and pancreatic beta cells, is responsible for glucose sensing and uptake. Loss of GLUT2 expression leads to organ damage, persistent hyperglycemia and diabetes [18]. Insulin promotes the uptake, utilization and storage of glucose by stimulating glycolytic enzyme phosphofructokinase (PFK) and repressing gluconeogenesis and glycogenolysis enzymes, phosphoenolpyruvate carboxykinase (PCK) and glycogen phosphorylase (PYGL) [19]. Insulin activity is initiated by the binding and autophosphorylation of tyrosine residues on the insulin receptor (IR). The activated receptor phosphorylates the insulin receptor substrate 1 (IRS-1). Phosphorylated IRS-1 (pIRS-1) recruits phosphatidylinositide (PI) 3-kinase (PI3K) (p85/p110 subunits) to the plasma membrane which stimulates PI3K-mediated phosphorylation of Akt. Glycogen synthesis kinase (GSK-3) is phosphorylated and inactivated by pAkt; relieving its inhibitory phosphorylation of glycogen synthase (GS), promoting glycogen synthesis. pIRS-1 activates the extracellular signal-regulated kinases (ERK) and mitogen-activated protein kinases (MAPK) pathway in parallel which can be used as a marker for the activation of proximal insulin signaling [20,21]. Underlying insulin resistance in type 2 diabetes has been attributed to defects in one or more components of the insulin signaling cascade [22]. Thus, while previous studies have shown PAT causes changes in PI3K/Akt and ERK/MAPK signaling, little is understood about the metabolic implications thereof [23].
Elevated glucose levels resulting from hepatic glucose production are a feature of type 2 diabetes. Insulin resistance precedes increased PCK and PYGL expression causing glucose efflux and hyperglycemia [19]. Previous studies in animals have referred to PAT as diabetogenic describing elevated glucose levels, depleted glycogen stores and mitochondrial dysfunction following PAT exposure, but mechanistic data in human models are lacking [15,24,25]. PAT toxicity has been described previously in the liver and kidney—both of which have high metabolic demands and are regulators in glucose homeostasis [11,17,26,27]. This study aimed to determine the effects of PAT on insulin signaling and metabolic flexibility in HepG2 and HEK293 cells.

2. Results

2.1. PAT Alters Expression of Enzymes Involved in Glucose Generation

Previous studies have alluded to PAT as a diabetogenic agent [15]. In a preliminary screening, HEK293 and HepG2 cells were exposed to a high glucose (25 mM) medium and PAT for 24 h. qPCR was then used to measure gene expression of enzymes vital to glucose homeostasis.
PFK-2, a key enzyme in glycolysis, was not altered by PAT in HEK293 cells (Figure 1A; p = 0.7270) but decreased significantly in HepG2 cells (Figure 1B; p = 0.0231; 10-fold). Although overall statistical significance was found for glycogenolysis initiator, PYGL, in both cell lines (HEK293 (Figure 1A; p = 0.0137)), post-hoc tests found that only the distinct two-fold increase in HepG2 cells was significant when compared to the control (Figure 1B; p = 0.0218)]. PCK-1, a rate limiting enzyme in gluconeogenesis, was significantly altered by PAT at 2 μM in both cell lines, though trends differed between them (HEK293 cells (Figure 1A; p = 0.0112) and HepG2 cells (Figure 1B; p = 0.0214)). This outcome provides a preliminary indication that PAT caused a shift from glycolysis to gluconeogenesis and glycogenolysis in HepG2 cells with HG media. Most significant changes were observed at 2 μM PAT–above the established safety concentration for PAT in consumables.

2.2. Glucose Availability Determines PAT-Associated Insulin Signaling Defects in HepG2 Cells

IR activation triggers phosphorylation of the receptor and IRS-1. Under NG conditions, PAT stimulated IRS-1 phosphorylation (pIRS-1) (Figure 2A; p = 0.0388), though pIR showed no statistical change (Figure 2A; p = 0.0775). This trend was potentiated in the presence of insulin shown by a significant two-fold increase in pIR (Figure 2B; p = 0.0180) and pIRS-1 (Figure 2B; p = 0.0145) in PAT-exposed NG i+ HepG2 cells, exhibiting a similar effect to the positive control, metformin.
This observation was dramatically reversed under hyperglycemic conditions. PAT caused significant two-fold decreases in both pIR (Figure 2C; p = 0.0178) and pIRS-1 (Figure 2C; p = 0.0213) in HG HepG2 cells. This result was consistent following insulin pathway stimulation (HG i+ HepG2) where both pIR (Figure 2D; p = 0.0182) and pIRS-1 (Figure 2D; p = 0.0188) were decreased in PAT treatments. These findings are suggestive of defects in insulin signaling under HG conditions following PAT exposure.

2.3. PAT-Altered ERK/MAPK Signaling Is Influenced by Glucose and Insulin Availability

Insulin-activated ERK phosphorylation is connected to the downstream regulation of transcription factors involved in metabolic homeostasis. Under NG conditions, PAT increased ERK activation in both HEK293 and HepG2 cells evidenced by increased pERK relative to total ERK (NG HEK293 (Figure 3A; pERK: p = 0.00610; ERK; p = 0.0032); NG HepG2 (Figure 3C; pERK: p = 0.0072; ERK: p = 0.0788)).
Conversely, under HG conditions, PAT-exposed HEK293 cells significantly decreased both pERK (Figure 3B; p = 0.0221) and total ERK (Figure 3B; p = 0.0053) expression. This observation was consistent in HG HepG2 cells (Figure 3D; pERK: p = 0.0104 and ERK: p = 0.0149). Interestingly, the effects of PAT on ERK signaling in HepG2s under both NG and HG were neutralized in the presence of insulin. No significant effects on ERK activation were observed in PAT-exposed NG i+ HepG2 (Figure 3E; pERK: p = 0.0630 and ERK: p = 0.0399) or HG i+ HepG2 (Figure 3F; pERK: p = 0.2027; and ERK: p = 0.0920) treatments.
PAT-altered ERK signaling trends were dissimilar to positive control metformin results, indicating a potential alternate mechanism of action. These data suggest that PAT stimulates ERK/MAPK signaling under NG conditions and inhibits signaling under HG conditions. These effects can, however, be counteracted by stimulating the insulin signaling pathway (Figure 3).

2.4. Glucose Availability Affects PAT-Mediated PI3K/Akt Signaling Trends

Insulin-stimulated PI3K activity directs the phosphorylation and activation of downstream target Akt. In PAT-treated NG HEK293 cells, PI3K (Figure 4A; p = 0.0051) and pAkt (Figure 4A; p = 0.0329) were significantly decreased while total inactive Akt (Figure 4A; p = 0.0160) increased. However, in NG HepG2 and NG i+ HepG2 cells PAT significantly increased the PI3K/Akt pathway activation evidenced by increased PI3K and pAkt expression relative to total Akt (NG HepG2 (Figure 4C; PI3K: p = 0.1431; pAkt: p = 0.0043; Akt: p = 0.0027); NG i+ HepG2 (Figure 4E; PI3K: p = 0.0112; pAkt: p = 0.0249; Akt: p = 0.0237)).
Conversely, PI3K/Akt pathway activation significantly decreased under all PAT HG conditions (HG HEK293 (Figure 4B; PI3K, p = 0.0043; pAkt, p = 0.0072; Akt, p = 0.0092); HG HepG2 (Figure 4D; PI3K, p = 0.0219; pAkt, p = 0.0115; Akt, p = 0.0053); HG i+ HepG2 (Figure 4F; PI3K: p = 0.0160; pAkt: p = 0.0415; Akt: p = 0.1681)).
These results show PAT stimulated PI3K/Akt signaling under NG conditions and inhibited PI3K/Akt activation under HG conditions despite insulin action. This indicated a possible PAT-induced defect in response to elevated glucose levels and insulin-stimulated signaling.

2.5. PAT-Modified GSK-3 Activation Corresponded with PI3K/Akt Signaling Trends While GLUT2 Expression Was Widely Compromised by PAT

Active GSK-3 phosphorylates and inhibits GS, preventing glycogen synthesis. Insulin action phosphorylates and inhibits GSK-3 (pGSK-3) via PI3K/Akt signaling, which enhances glycogen synthesis. Under NG conditions, PAT significantly increased pGSK-3 and decreased total active GSK-3 in both HEK293 and HepG2 cells suggestive of decreased GSK activity (NG HEK293 (Figure 5A; pGSK-3: p = 0.0073; GSK-3: p = 0.0488); NG HepG2 (Figure 5C; pGSK-3: p = 0.0415; GSK-3: p = 0.0216)).
In HG, the media effects were reversed, exhibiting GSK-3 activation in both cell lines. In HG HEK293 cells, inactive pGSK-3 decreased (Figure 5B; p = 0.0158) and total active GSK-3 increased (Figure 5C; p = 0.0216). This effect was more pronounced in PAT-treated HG HepG2 cells (Figure 5D; pGSK-3: p = 0.0158; GSK-3: p = 0.0149)—indicative of compromised glycogen synthesis. When stimulated with insulin, inactive pGSK-3 remained decreased in HG i+ HepG2 cells (Figure 5F; p = 0.0056). No changes were noted in NG i+ HepG2 cells in either pGSK-3 (Figure 5E; p = 0.3815) or GSK-3 (Figure 5E; p = 0.4969). These results suggest PAT caused defects in the GSK-3 signaling axis under HG conditions.
GLUT2, involved in glucose sensing and uptake, is linked to impaired glucose-stimulated insulin signaling when suppressed. PAT did not alter GLUT2 expression under NG conditions in both HEK293 and HepG2 cells (NG HEK293 (Figure 5A; p = 0.0556); NG HepG2 (Figure 5C; p = 0.0559)). In the presence of glucose and insulin, however, PAT significantly decreased GLUT2 expression in both cell lines (NG i+ HepG2 cells (Figure 5E; p = 0.0496); HG HEK293 (Figure 5B; p = 0.0048); HG HepG2; (Figure 5D; p = 0.0077); HG i+ HepG2 cells (Figure 5F; p = 0.0281)). This suggests PAT impaired GLUT2-mediated glucose sensing and uptake under conditions of increased glucose and insulin availability.

2.6. PAT Contributes to Metabolic Inflexibility by PDK-1 Elevation and PDH Inhibition under NG and HG Conditions

Active PDH, stimulated by insulin, catalyzes the conversion of pyruvate to acetyl-CoA. Inhibition of PDH is catalyzed by PDK-mediated phosphorylation on the E1α subunit.
PAT did not alter PDK-1 and PDH E1α expression in HEK293 cells (NG (Figure 6A; PDK-1: p = 0.1390; PDH E1α: p = 0.2220); HG (Figure 6B; PDK-1: p = 0.2223; PDH E1α: p = 0.1417)). pPDH E1α expression remained unchanged in NG HEK293 cells (Figure 6A; p = 0.3588) but decreased in HG HEK293 cells (Figure 6B; p = 0.0221).
PAT-mediated effects on this pathway were more distinct in HepG2 cells. PDK-1 expression significantly increased in PAT-treated HepG2 cells under all conditions (NG (Figure 6C; p = 0.0060), HG (Figure 6D; p = 0.0186), NG i+ (Figure 6E; p = 0.0048), HG i+ (Figure 6F; p = 0.0081)). An associated increase in (inactive) pPDH E1α (NG (Figure 6C; p = 0.0045), HG (Figure 6D; p = 0.0041), NG i+ (Figure 6E; p = 0.0041) and HG i+ (Figure 6F; p = 0.0179)) with a concomitant decrease in PDH E1α (NG (Figure 6C; p = 0.0060), HG (Figure 6D; p = 0.0055), NG i+ (Figure 6E; p = 0.0032) and HG i+ (Figure 6F; p = 0.0124)) was observed under these conditions in PAT treatments. This was indicative of PDK-1-mediated PDH inhibition in PAT-treated HepG2 cells.
Elevated pPDH E1α suppresses aerobic pyruvate oxidation and can aggravate the Warburg effect. This pathway, characterized predominantly in cancerous cells, favors the anaerobic conversion of pyruvate to lactate. This may explain the distinct differences in PDH E1α results between HepG2 (cancerous) and HEK293 (non-cancerous) cells. Interestingly, lactate levels increased significantly in controls under all HG conditions relative to NG (Table 1; (HEK293; p = 0.0006) (HepG2; p = 0.0013) (HepG2 i+; p = 0.0190)). The highly significant increase observed in HEK293 cells relative to HepG2 cells may be related to metabolic differences in cancerous and non-cancerous cells as well as the pH sensitivity of HEK293 cells. Interestingly, a significant decrease in lactate levels was observed in PAT treatments relative to the controls in NG treatments and HEK293 cells (Table 1; NG HEK293 (p = 0.0222); HG HEK293 (p = 0.0069); NG HepG2 (p = 0.0142); NG i+ (p = 0.0069)). HG HepG2 and HG i+ HepG2 treatments however, (Table 1; NG HepG2 (p = 0.4336); NG i+ (p = 0.7427)) were not statistically changed. This lack of lactate elevation despite changes to the PDH axis in PAT treatments suggests pyruvate was possibly shunted back towards gluconeogenesis or to an alternative fate instead of reduction to lactate by LDH.

3. Discussion

The key finding in this study is that exposure to PAT impairs insulin signaling under HG conditions and alters metabolic flexibility after 24 h exposure in an in vitro model. This finding was consistent following insulin stimulation, suggestive of an insulin-resistant mechanism.
A recent study showed PAT was cytotoxic to rat pancreatic β cells but did not affect insulin production [24,25] prompting examination of the insulin signaling cascade in this study. The IR, a tyrosine kinase, undergoes autophosphorylation catalyzing the phosphorylation and activation of downstream cellular proteins including IRS-1, the PI3K/Akt pathway and ERK/MAPK pathway. These pathways act in concert to positively regulate glycolysis, glucose storage as glycogen and lipids and repress glucose synthesis and release by inhibiting glycogenolysis and gluconeogenesis. Insulin action is attenuated by dephosphorylation of the receptor and its substrates. Phospho-tyrosine residues indicated PAT activated the insulin signaling cascade under NG conditions but suppressed activation under HG conditions in HepG2 cells (Figure 2). Defects in this pathway have been linked to impaired glucose tolerance and the pathogenesis of type 2 diabetes [22,28].
The ERK/MAPK pathway is activated in a stepwise sequence within the insulin signaling cascade. pERK catalyzes the activation of transcription factors to initiate cell proliferation. Inhibition of this pathway observed in PAT exposed HG HepG2 and HEK293 cells (Figure 3) prevents insulin-stimulated cell growth. PAT-induced alterations in ERK signaling and proliferation have been reported in the literature, but metabolic consequences have been neglected [4,23]. The findings in this study imply PAT-mediated ERK changes are dependent on insulin and glucose availability (Figure 3). This may be of consequence to glucose metabolism under conditions of PAT-inflicted β-cell death [24].
Proximal insulin signaling activates the PI3K/Akt pathway in parallel to the ERK/MAPK pathway. pIRS-1 recruits PI3K to activate Akt by phosphorylation. pAkt-mediated phosphorylation of GSK-3 (ser 9) relieves GS inhibition and promotes glycogen synthesis. Under NG conditions, PAT-activated pIRS-1 (Figure 2), PI3K/Akt activation (Figure 4) and increased pGSK-3 (Figure 5) in HepG2 cells positively regulating glycogen synthesis. Under HG conditions, however, PAT diminished pIRS-1 (Figure 2) in HepG2 cells and PI3K/Akt (Figure 4) mediated GSK-3 (Figure 5) phosphorylation in both HepG2 and HEK293 cells. These findings reveal distinct differences in PAT-mediated signaling depending on glucose availability. PAT-altered PI3K/Akt signaling has been reported previously in other cell lines [23]; the findings in this study, however, reveal novel metabolic implications. These trends identified in HepG2 cells were observed consistently in both the presence and absence of insulin, implicating a non-insulin dependent mechanism. Elevated total GSK-3 is associated with impaired glucose disposal and glycogen synthesis and type 2 diabetes [20]. Similar dysfunctions in reduced pIRS-1/PI3K/Akt signaling as observed in this study, have been associated with insulin resistance and impaired glucose tolerance [21,29].
Previous studies describe PAT-inflicted glycogen loss and serum glucose elevation in animals, postulating that PAT increases gluconeogenesis and glycogenolysis [15,30]. In this study, active GSK-3, a prominent feature in glycogenolysis, is elevated by PAT under HG conditions in both HEK293 and HepG2 cell lines (Figure 5). PAT also increased the gene expression of glucose-producing enzymes PYGL and PCK-1 and inhibited glycolytic PFK-1 (Figure 1) under the same conditions in HepG2s. These classic indicators of glycogenolysis and gluconeogenesis, usually inhibited by insulin and HG conditions [28], were increased by PAT under the same conditions. Glucose homeostasis relies on the detection of varying glucose availability. GLUT2, expressed in the kidney and liver, plays a crucial role in glucose sensing and uptake. GLUT2 suppression, induced by PAT in both HEK293 and HepG2 cells (Figure 5), is associated with cellular glucose efflux, impaired activity of glucose sensitive genes, reduced glucose uptake and promoting type 2 diabetes pathogenesis and organ damage [18,31]. While organ damage has been described in previous findings on PAT, this novel finding offers a possible explanation for the increased gluconeogenic markers, impaired glycogen synthesis and glycolysis in PAT treatments in this study.
These findings indicate that PAT compromised cellular metabolic processes in adaption to glucose availability. PDH, the principal enzyme controlling nutrient adaption and metabolic flexibility, is activated by insulin and glucose via dephosphorylation on the E1α subunit. PDH metabolizes pyruvate at the junction between glucose, fatty acid metabolism and the TCA cycle [17]. PDK-1 phosphorylates and inhibits PDH E1α under hypoxic conditions, shifting metabolism to glycolytic processes [32]. PAT significantly increased PDK-1 and pPDH E1α expression in HepG2 cells (Figure 6). In cancerous cells such as HepG2s, this is associated with aggravation of the Warburg effect. The Warburg effect posits cancerous cells inhibit mitochondrial ATP production and increase rates of glycolysis and cytoplasmic conversion of pyruvate to lactate [33,34]. This pathway is linked to glucose scarcity, synthesis and inhibition of pyruvate conversion to acetyl-CoA. Mitochondrial inhibition in cancerous cells is achieved by PDK and pPDH elevation. These actions block excessive mitochondrial ROS production, linked extensively to PAT in previous studies [14]. Thus, PAT-induced pPDH and PDK-1 elevation may be an energy- and mitochondrial conservation strategy [4,10,11]. In addition, lactate levels were decreased in PAT treatments (Table 1), despite PDK-1 and pPDH E1α (Figure 6) elevation. While the lower levels of lactate in i+ treatments suggest insulin may have stimulated mitochondrial function, the high levels in the HEK293 control cells may explain the potent toxicity of PAT in the cell line as PAT loses biological activity in alkaline media [35,36]. Taken together, the results imply pyruvate did not undergo lactic acid fermentation as suggested in the Warburg effect theory. Alternate fates of pyruvate under PDH inhibition include the TCA cycle, fatty acid synthesis and gluconeogenesis [17]. While there is currently insufficient evidence in this study and the literature to conclusively rule out the TCA cycle or fatty acid synthesis these findings, together with gluconeogenic enzyme mRNA levels (Figure 1), GLUT2 and GSK-3 expression (Figure 5), infer pyruvate was shunted back toward gluconeogenesis despite the availability of glucose and insulin. Decreased PDH and metabolic inflexibility are initiating events in impaired glucose oxidation, associated with insulin resistance and type 2 diabetes [14,16,37,38,39].
Type 2 diabetes is characterized by elevated glucose levels, impaired glucose tolerance, insulin resistance, defects in the insulin signaling pathway, oxidative stress and mitochondrial dysfunction [22]. The literature shows PAT causes oxidative stress and mitochondrial dysfunction which is associated with both causes and consequences of insulin resistance [10,11,26,40]. This study presents novel findings indicating PAT opposes insulin action under HG conditions, suppresses components of the insulin signaling pathway and prevents metabolic flexibility in HepG2 and HEK293 cells. Given that PAT targets the kidney and liver, and the role of these organs in systemic glucose and energy homeostasis, this has strong implications for PAT-induced toxicology and disorders of metabolism.

4. Conclusions

Our findings show PAT caused defects in the insulin signaling pathway under HG conditions, stimulated glucose production pathways and inhibited PDH activity, contributing to metabolic inflexibility. Collectively, these results suggest PAT exposure may be an initiating event in insulin resistance with an etiological role in pathogenesis of type 2 diabetes and other disorders of metabolism. Significant results were observed above and below the safety level of PAT.

5. Materials and Methods

HEK293 and HepG2 cells were obtained from the American Type Culture Collection (Johannesburg, South Africa). Culture reagents were purchased from Lonza BioWhittaker (Basel, Switzerland). Western Blotting and qPCR reagents and consumables were purchased from Bio-Rad (Hercules, CA, USA). Patulin (P1639) was purchased from Sigma-Aldrich (St. Louis, MO, USA). All other reagents were obtained from Merck (Darmstadt, Germany) unless otherwise stated.

5.1. Cell Culture

HepG2 cells were cultured in complete culture medium (CCM) containing Eagle’s minimum essential medium (EMEM) supplemented with 2 mM l-glutamine, 1% pen-strep-fungizone (500 units potassium penicillin, 500 μg streptomycin, 1.25 μg amphotericin B/5 mL flask) and 10% fetal bovine serum in 25 cm3 flasks at 37 °C. HepG2 cells were derived from hepatocellular carcinoma. Despite the limitations of being a cancerous line (relative to primary human hepatocytes), HepG2 cells were used as they exhibit phenotypic stability, genotypic features of normal liver cells and exhibit high glucose consumption and active energy metabolism [41,42]. HEK293 cells were cultured in CCM in comprising Dulbecco’s modified essential medium (DMEM) supplemented with 2 mM l-glutamine, 1% pen-strep-fungizone (500 units potassium penicillin, 500 μg streptomycin, 1.25 μg amphotericin B/5 mL flask), 10 mM HEPES and 10% fetal bovine serum in 25 cm3 flasks at 37 °C; 5% CO2. HEK293 cells are established from primary human embryonic kidney and have the capacity to switch metabolic processes from glucose consumption and lactate production to glucose–lactate co-consumption [43]. This characteristic makes HEK293 cells an ideal model to study potential changes to glucose metabolism as a result of PAT exposure.

5.2. Dosage Information

PAT (5 mg) was dissolved in 1ml 100% dimethyl sulfoxide (DMSO) (32 mM PAT). Smaller PAT stock solutions were prepared in 0.1 M PBS to a final concentration of 1 mM. When 90% confluent, cells were serum starved for 16 h (h) and then treated with PAT (0.2 μM; 2.0 μM) in 5 mL CCM for 24 h. These PAT concentrations are below and above the safety level of PAT in consumables, respectively, and were determined from incidence and monitor studies [3,5]. These studies indicate that despite a safety level of 50 µg/L (0.3 µM), PAT exposure and levels in consumables can vary from 0.1 µM to 4.0 µM. Cells grown and treated under these conditions (normoglycemic: 5 mM glucose) are referred to as NG in the results.
To determine the effect of PAT on glucose tolerance, once 90% confluent HepG2 and HEK293 cells were serum starved for 16 h and exposed to high glucose CCM (HG) (25 mM) and PAT (0.2 μM; 2.0 μM) for 24 h.
Finally, to determine PAT effect on insulin signaling, 90% confluent HepG2 cells were serum starved for 16 h, exposed to NG (5 mM glucose) or HG (25 mM glucose) media and PAT (0.2 μM; 2.0 μM) for 24 h. Cells were then stimulated with 10 ng/mL (1.7 nM) insulin for 5 min before the media was removed. These are represented by NG i+ and HG i+ in the results. HEK293 cells show a limited insulin signaling profile and were excluded from this parameter in the study.
Metformin (5 mM) was used as a positive control in all protein expression experiments; this concentration was selected from the literature [44].
Results are representative of three independent experiments completed in triplicate.

5.3. Quantitative Polymerase Chain Reaction (PCR)

5.3.1. RNA Isolation and cDNA Preparation

RNA was isolated adding 500 μL QIAzol lysis reagent (Qiagen, Hilden, Germany) to 1 × 106 cells in 500 μL 0.1 M PBS and incubated overnight (−80 °C). Chloroform (100 µL) was then added and samples were centrifuged (15 min, 12,000× g, 4 °C). Isopropanol (250 µL) was added to the aqueous phase in a clean tube and incubated overnight (−80 °C). Samples were centrifuged (20 min, 12,000× g, 4 °C), supernatant was discarded and pellets were washed with 500 µL cold ethanol and centrifuged (15 min, 7400× g, 4 °C) once more. Ethanol was then aspirated; samples were dried and resuspended in 12.5 µL RNase-free water. RNA was quantified using the Nanodrop2000 and standardized to 1000 µg/μL. cDNA was synthesized using Bio-Rad iScript™ reaction mix as per the manufacturer’s instructions (iScript™ cDNA Synthesis kit Bio-Rad; 107-8890, Johannesburg, South Africa). Thermocycler conditions were 25 °C for 5 min, 42 °C for 30 min, 85 °C for 5 min and a final hold at 4 °C.

5.3.2. mRNA Quantification

mRNA levels of glucose homeostasis enzymes PYGL, PFK-1 and PCK-1 were evaluated using the SsoAdvanced™ Universal SYBR Green Supermix (Bio-Rad; 170-880) according to the manufacturer’s instructions. Once synthesized (as above), a reaction volume made up to 25 µL comprising cDNA template, 30 nM sense primer, 30 nM antisense primer, reaction mix and nuclease-free water was made up. Primer sequences and annealing temperatures were as follows PYGL [Sense 5′-TGCCCGGCTACATGAATAACA-3′; Antisense 5′-TGTCATTGGGATAGAGACCC-3′; 56.5 °C]; PCK-1 [Sense 5′-AAAACGGCCTGAACCTCTCG-3′; Antisense 5′-ACACAGCTCAGCGTTATTCTC-3′; 56.5 °C]; PFK-2 [Sense 5′AGTCCTACGACTTCTTTCGGC-3′; Antisense 5′-TCTCCTCAGTGAGATACGCCT-3′; 57 °C] qPCR was completed using CFX Touch™ Real Time PCR Detection System (Bio-Rad, Johannesburg, South Africa). The reaction was subjected to an initial denaturation (95 °C, 4 min), followed by 37 denaturation cycles (95 °C, 15 s), annealing (primer-specific temperature, 40 s), extension (72 °C, 30 s) and a plate read for 37 cycles. β actin [Sense 5′-TGACGGGTCACCCACACTGTGCCCAT-3′; Antisense 5′-CTAGAAGCATTTGCGGTGGACGATGGAGGG-3′] was run under the same conditions and used as the housekeeping gene. Data were analyzed using the method described by Livak and Schmittgen and represented as fold change (2−ΔΔCT) relative to the control [45].

5.4. Western Blotting

5.4.1. Protein Isolation

Cytobuster (Novagen®, Pretoria, South Africa) supplemented with protease inhibitor and phosphatase inhibitor (Roche 05892791001 and 04906837001, respectively) was added to cells (4 °C, 10 min) and centrifuged (5 min, 10,000× g, 4 °C). Crude protein extracts were quantified using the bichinchonic acid (BCA) assay (Sigma, St. Louis, MO, USA) and standardized to 1 mg/mL. Samples were denatured by boiling (5 min, 100 °C) in Laemmli buffer (dH2O, 0.5 M TrisHCl (pH 6.8), glycerol, 10% sodium dodecyl sulphate polyacrylamide (SDS), β-mercaptoethanol, 1% bromophenol blue).

5.4.2. Sodium Dodecyl Sulphate–Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Immunoblotting

Samples were separated by electrophoresis on 7% SDS gels (1 h, 150 V) and transferred to nitrocellulose membranes using the TransBlot Turbo System® (Bio-Rad, Johannesburg, South Africa). Membranes were blocked (1 h, 3%, bovine serum albumin (BSA)) in Tris-buffered saline with Tween20 (TTBS) (20 mM Tris–HCl; pH 7.4), 500 mM NaCl and 0.01% Tween 20). Membranes were then incubated with primary antibody (phosphor-tyrosine (p-tyr100) (CST#9411); phosphor-GSK3β (ser 9) (pGSK3) (ab107166); total GSK3α/β (ab15314); GLUT2 (ab54460); p44/42 MAPK (ERK1/2) (CST#9102); phosphor-p44/42 MAPK (ERK1/2) (Thr202/Try204) (CST#9106); PI3K (CST#5405); phosphor-ser473 Akt (CST#9271); Akt (CST#9272); PDK-1 (ab110025); phosphor-PDH (E1α) (ab92696); PDH (E1α) (ab110330); (1:1000)) in 1% BSA in TTBS overnight at 4 °C. Membranes were washed four times (10 mL, TTBS, 10 min) and treated with horseradish peroxidase-conjugated secondary antibody (anti-rabbit, CST #7074; anti-mouse, CST #7076, 1:10,000) in 1% BSA for one hour at room temperature. Membranes were then washed four times (10 mL, TTBS, 10 min) and immunoreactivity was detected (Clarity™ Western ECL Blotting Substrate, Bio-Rad, Johannesburg, South Africa) with the Bio-Rad ChemiDoc Imaging System. Protein bands were analyzed with the Bio-Rad Image Lab Analysis 6.0 software and normalized against the corresponding β-actin bands.

5.5. Statistical Analysis

Results are represented as mean fold change ± standard deviation (SD) relative to normalized control. Statistical significance was assessed using one-way ANOVA with appropriate post hoc comparisons on GraphPad Version 5.0 Software. p values less than 0.05 were considered significant.

Author Contributions

Conceptualization, A.C. and Y.P.; methodology, Y.P. and S.N.; lab investigation and formal analysis, Y.P.; funding and resources, A.C. and Y.P.; writing—original draft preparation, Y.P.; writing—review and editing, A.C. and S.N.; supervision, A.C. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Research Foundation (Grant UID: 98323), and the University of KwaZulu-Natal College of Health Science.

Institutional Review Board Statement

Ethical review was waived as this study did not involve human or animal subjects.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Islam, S.M.S.; Purnat, T.D.; Phuong, N.T.A.; Mwingira, U.; Schacht, K.; Fröschl, G. Non-Communicable Diseases (NCDs) in developing countries: A symposium report. Glob. Health 2014, 10, 81. [Google Scholar] [CrossRef] [Green Version]
  2. Martins, I.J. Overnutrition Determines LPS Regulation of Mycotoxin Induced Neurotoxicity in Neurodegenerative Diseases. Int. J. Mol. Sci. 2015, 16, 29554–29573. [Google Scholar] [CrossRef] [Green Version]
  3. Pal, S.; Singh, N.; Ansari, K.M. Toxicological effects of patulin mycotoxin on the mammalian system: An overview. Toxicol. Res. 2017, 6, 764–771. [Google Scholar] [CrossRef] [Green Version]
  4. Liu, B.-H.; Wu, T.-S.; Yu, F.-Y.; Su, C.-C. Induction of Oxidative Stress Response by the Mycotoxin Patulin in Mammalian Cells. Toxicol. Sci. 2007, 95, 340–347. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Sant’Ana, A.d.S.; Rosenthal, A.; de Massaguer, P.R. The fate of patulin in apple juice processing: A review. Food Res. Int. 2008, 41, 441–453. [Google Scholar] [CrossRef] [Green Version]
  6. Pfeiffer, E.; Gross, K.; Metzler, M. Aneuploidogenic and clastogenic potential of the mycotoxins citrinin and patulin. Carcinogenesis 1998, 19, 1313–1318. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Alves, I.; Oliveira, N.; Laires, A.; Rodrigues, A.; Rueff, J. Induction of micronuclei and chromosomal aberrations by the mycotoxin patulin in mammalian cells: Role of ascorbic acid as a modulator of patulin clastogenicity. Mutagenesis 2000, 15, 229–234. [Google Scholar] [CrossRef] [Green Version]
  8. Schumacher, D.M.; Metzler, M.; Lehmann, L. Mutagenicity of the mycotoxin patulin in cultured Chinese hamster V79 cells, and its modulation by intracellular glutathione. Arch. Toxicol. 2005, 79, 110–121. [Google Scholar] [CrossRef] [PubMed]
  9. Glaser, N.; Stopper, H. Patulin: Mechanism of genotoxicity. Food Chem. Toxicol. 2012, 50, 1796–1801. [Google Scholar] [CrossRef]
  10. Zhang, B.; Peng, X.; Li, G.; Xu, Y.; Xia, X.; Wang, Q. Oxidative stress is involved in Patulin induced apoptosis in HEK293 cells. Toxicon 2015, 94 (Suppl. C), 1–7. [Google Scholar] [CrossRef]
  11. Zhong, Y.; Jin, C.; Gan, J.; Wang, X.; Shi, Z.; Xia, X.; Peng, X. Apigenin attenuates patulin-induced apoptosis in HEK293 cells by modulating ROS-mediated mitochondrial dysfunction and caspase signal pathway. Toxicon 2017, 137, 106–113. [Google Scholar] [CrossRef]
  12. Tsai, W.T.; Lo, Y.C.; Wu, M.S.; Li, C.Y.; Kuo, Y.P.; Lai, Y.H.; Tsai, Y.; Chen, K.C.; Chuang, T.H.; Yao, C.H.; et al. Mycotoxin patulin suppresses innate immune responses by mitochondrial dysfunction and p62/sequestosome-1-dependent mitophagy. J. Biol. Chem. 2016, 291, 19299–19311. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Puel, O.; Galtier, P.; Oswald, I. Biosynthesis and toxicological effects of patulin. Toxins 2010, 2, 613–631. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Kim, J.-W.; Tchernyshyov, I.; Semenza, G.L.; Dang, C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3, 177–185. [Google Scholar] [CrossRef] [Green Version]
  15. Sakthisekaran, D.; Shanmugasundaram, K.R.; Shanmugasundaram, E.R. Effect of patulin on some enzymes of carbohydrate metabolism studied in rats. Biochem. Int. 1989, 19, 37–51. [Google Scholar] [PubMed]
  16. Tao, R.; Xiong, X.; Harris, R.A.; White, M.F.; Dong, X.C. Genetic inactivation of pyruvate dehydrogenase kinases improves hepatic insulin resistance induced diabetes. PLoS ONE 2013, 8, e71997. [Google Scholar] [CrossRef] [Green Version]
  17. Zhang, S.; Hulver, M.W.; McMillan, R.P.; Cline, M.A.; Gilbert, E.R. The pivotal role of pyruvate dehydrogenase kinases in metabolic flexibility. Nutr. Metab. 2014, 11, 10. [Google Scholar] [CrossRef] [Green Version]
  18. Cohen, M.; Kitsberg, D.; Tsytkin, S.; Shulman, M.; Aroeti, B.; Nahmias, Y. Live imaging of GLUT2 glucose-dependent trafficking and its inhibition in polarized epithelial cysts. Open Biol. 2014, 4, 140091. [Google Scholar] [CrossRef] [Green Version]
  19. Haeusler, R.A.; Camastra, S.; Astiarraga, B.; Nannipieri, M.; Anselmino, M.; Ferrannini, E. Decreased expression of hepatic glucokinase in type 2 diabetes. Mol. Metab. 2015, 4, 222–226. [Google Scholar] [CrossRef]
  20. Henriksen, E.J.; Dokken, B.B. Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Curr. Drug Targets 2006, 7, 1435–1441. [Google Scholar] [CrossRef]
  21. Maffucci, T.; Brancaccio, A.; Piccolo, E.; Stein, R.C.; Falasca, M. Insulin induces phosphatidylinositol-3-phosphate formation through TC10 activation. EMBO J. 2003, 22, 4178–4189. [Google Scholar] [CrossRef] [Green Version]
  22. Fröjdö, S.; Vidal, H.; Pirola, L. Alterations of insulin signaling in type 2 diabetes: A review of the current evidence from humans. Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 2009, 1792, 83–92. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Alam, S.; Pal, A.; Kumar, R.; Dwivedi, P.D.; Das, M.; Ansari, K.M. EGFR-mediated Akt and MAPKs signal pathways play a crucial role in patulin-induced cell proliferation in primary murine keratinocytes via modulation of Cyclin D1 and COX-2 expression. Mol. Carcinog. 2014, 53, 988–998. [Google Scholar] [CrossRef] [PubMed]
  24. Nisr, R.B.; Russell, M.A.; Chrachri, A.; Moody, A.J.; Gilpin, M.L. Effects of the microbial secondary metabolites pyrrolnitrin, phenazine and patulin on INS-1 rat pancreatic β-cells. FEMS Immunol. Med. Microbiol. 2011, 63, 217–227. [Google Scholar] [CrossRef] [PubMed]
  25. Al Seeni, M.N.; Ali, A.M.; Elsawi, N.M.; Abdo, A.S. Assessment of the Secondary Metabolite Patulin and Lycium Barbarum Fruit on INS-1 Rat Pancreatic Β-Cells. Agric. Food Sci. Res. 2017, 4, 24–29. [Google Scholar]
  26. Zhou, S.-M.; Jiang, L.-P.; Geng, C.-Y.; Cao, J.; Zhong, L.-F. Patulin-induced oxidative DNA damage and p53 modulation in HepG2 cells. Toxicon 2010, 55, 390–395. [Google Scholar] [CrossRef]
  27. Boussabbeh, M.; Ben Salem, I.; Prola, A.; Guilbert, A.; Bacha, H.; Abid-Essefi, S.; Lemaire, C. Patulin induces apoptosis through ROS-mediated endoplasmic reticulum stress pathway. Toxicol. Sci. 2015, 144, 328–337. [Google Scholar] [CrossRef] [Green Version]
  28. Saltiel, A.R.; Kahn, C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414, 799–806. [Google Scholar] [CrossRef] [Green Version]
  29. Brozinick, J.T.; Roberts, B.R.; Dohm, G.L. Defective Signaling Through Akt-2 and -3 But Not Akt-1 in Insulin-Resistant Human Skeletal Muscle. Diabetes 2003, 52, 935–941. [Google Scholar] [CrossRef] [Green Version]
  30. Devaraj, H.; Shanmugasundaram, K.; Shanmugasundaram, E. Changes in carbohydrate metabolism during Patulin toxicosis studied in chicks. J. Indian Inst. Sci. 2013, 64, 65. [Google Scholar]
  31. Thorens, B. GLUT2, glucose sensing and glucose homeostasis. Diabetologia 2015, 58, 221–232. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Zhang, W.; Zhang, S.L.; Hu, X.; Tam, K.Y. Targeting Tumor Metabolism for Cancer Treatment: Is Pyruvate Dehydrogenase Kinases (PDKs) a Viable Anticancer Target? Int. J. Biol. Sci. 2015, 11, 1390–1400. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Jha, M.K.; Suk, K. Pyruvate Dehydrogenase Kinase as a Potential Therapeutic Target for Malignant Gliomas. Brain Tumor Res. Treat. 2013, 1, 57–63. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Golias, T.; Papandreou, I.; Sun, R.; Kumar, B.; Brown, N.V.; Swanson, B.J.; Pai, R.; Jaitin, D.; Le, Q.-T.; Teknos, T.N.; et al. Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours. Sci. Rep. 2016, 6, 31146. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Chain, E.; Florey, H.W.; Jennings, M.A. An antibacterial substance produced by Penicillium claviforme. Br. J. Exp. Pathol. 1942, 23, 202. [Google Scholar]
  36. Liste-Calleja, L.; Lecina, M.; Lopez-Repullo, J.; Albiol, J.; Solà, C.; Cairó, J.J. Lactate and glucose concomitant consumption as a self-regulated pH detoxification mechanism in HEK293 cell cultures. Appl. Microbiol. Biotechnol. 2015, 99, 9951–9960. [Google Scholar] [CrossRef]
  37. Mondon, C.E.; Jones, I.R.; Azhar, S.; Hollenbeck, C.B.; Reaven, G.M. Lactate production and pyruvate dehydrogenase activity in fat and skeletal muscle from diabetic rats. Diabetes 1992, 41, 1547–1554. [Google Scholar] [CrossRef]
  38. Montes, M.; Chicco, A.; Lombardo, Y.B. The effect of insulin on the uptake and metabolic fate of glucose in isolated perfused hearts of dyslipemic rats. J. Nutr. Biochem. 2000, 11, 30–37. [Google Scholar] [CrossRef]
  39. Alves, T.C.; Befroy, D.E.; Kibbey, R.G.; Kahn, M.; Codella, R.; Carvalho, R.A.; Petersen, K.F.; Shulman, G.I. Regulation of hepatic fat and glucose oxidation in rats with lipid-induced hepatic insulin resistance. Hepatology 2011, 53, 1175–1181. [Google Scholar] [CrossRef] [Green Version]
  40. Lim, S.; Ahn, S.Y.; Song, I.-C.; Chung, M.H.; Jang, H.C.; Park, K.S.; Lee, K.-U.; Pak, Y.K.; Lee, H.K. Chronic exposure to the herbicide, atrazine, causes mitochondrial dysfunction and insulin resistance. PLoS ONE 2009, 4, e5186. [Google Scholar] [CrossRef]
  41. Gerets, H.H.J.; Tilmant, K.; Gerin, B.; Chanteux, H.; Depelchin, B.O.; Dhalluin, S.; Atienzar, F.A. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol. Toxicol. 2012, 28, 69–87. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Chen, Y.; Chen, Z.; Feng, J.H.; Chen, Y.B.; Liao, N.S.; Su, Y.; Zou, C.Y. Metabolic profiling of normal hepatocyte and hepatocellular carcinoma cells via (1) H nuclear magnetic resonance spectroscopy. Cell Biol. Int. 2018, 42, 425–434. [Google Scholar] [CrossRef] [PubMed]
  43. Martínez-Monge, I.; Albiol, J.; Lecina, M.; Liste-Calleja, L.; Miret, J.; Solà, C.; Cairó, J.J. Metabolic flux balance analysis during lactate and glucose concomitant consumption in HEK293 cell cultures. Biotechnol. Bioeng. 2019, 116, 388–404. [Google Scholar] [CrossRef] [PubMed]
  44. He, L.; Wondisford, F.E. Metformin action: Concentrations matter. Cell Metab. 2015, 21, 159–162. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25, 402–408. [Google Scholar] [CrossRef]
Toxins 15 00244 g001 550
Figure 1. PAT alters expression of enzymes involved in glucose production in hyperglycemic conditions. qPCR was used to assess expression of glucose homeostasis enzymes PYGL, PFK-1 and PCK-1 in (A) HEK239 and (B) HepG2 cells exposed to 25 mM glucose and PAT for 24 h (* p < 0.05 relative to control).
Figure 1. PAT alters expression of enzymes involved in glucose production in hyperglycemic conditions. qPCR was used to assess expression of glucose homeostasis enzymes PYGL, PFK-1 and PCK-1 in (A) HEK239 and (B) HepG2 cells exposed to 25 mM glucose and PAT for 24 h (* p < 0.05 relative to control).
Toxins 15 00244 g001
Toxins 15 00244 g002 550
Figure 2. PAT alters insulin signaling in HepG2 cells. Western blotting determined PAT-increased pIR and pIRS-1 in NG media (A) and under insulin stimulation (NG i+) (B). This effect was reversed in HG media (C) decreased pIRS-1 and pIR expression was observed which remained consistent under insulin-stimulated hyperglycemic conditions (HG i+) (D) (* p < 0.05 relative to control).
Figure 2. PAT alters insulin signaling in HepG2 cells. Western blotting determined PAT-increased pIR and pIRS-1 in NG media (A) and under insulin stimulation (NG i+) (B). This effect was reversed in HG media (C) decreased pIRS-1 and pIR expression was observed which remained consistent under insulin-stimulated hyperglycemic conditions (HG i+) (D) (* p < 0.05 relative to control).
Toxins 15 00244 g002
Toxins 15 00244 g003 550
Figure 3. PAT alters ERK/MAPK according to glucose and insulin availability. Western blotting determined PAT caused a significant increase in ERK1/2 phosphorylation activation relative to total ERK expression in NG HEK293 (A) and NG HepG2 (C) cells. This was reversed in HG HEK293 (B) and HG HepG2 (D) cells with decreases in pERK and ERK following 24 h PAT exposure. Both trends were neutralized in the presence of insulin (E,F) (** p < 0.01, * p < 0.05 relative to control).
Figure 3. PAT alters ERK/MAPK according to glucose and insulin availability. Western blotting determined PAT caused a significant increase in ERK1/2 phosphorylation activation relative to total ERK expression in NG HEK293 (A) and NG HepG2 (C) cells. This was reversed in HG HEK293 (B) and HG HepG2 (D) cells with decreases in pERK and ERK following 24 h PAT exposure. Both trends were neutralized in the presence of insulin (E,F) (** p < 0.01, * p < 0.05 relative to control).
Toxins 15 00244 g003
Toxins 15 00244 g004 550
Figure 4. PAT alters PI3K/Akt signaling according to glucose availability irrespective of insulin action. Western blotting established PAT significantly increased PI3K activation and Akt phosphorylation activation relative to total Akt expression in NG HEK293 (A) and NG HepG2 (C) cells. This was reversed in HG HEK293 (B) and HG HepG2 (D) cells with decreases in PI3K, pAkt following 24 h PAT exposure. Both trends were maintained in the presence of insulin (E,F) (* p < 0.05 relative to control).
Figure 4. PAT alters PI3K/Akt signaling according to glucose availability irrespective of insulin action. Western blotting established PAT significantly increased PI3K activation and Akt phosphorylation activation relative to total Akt expression in NG HEK293 (A) and NG HepG2 (C) cells. This was reversed in HG HEK293 (B) and HG HepG2 (D) cells with decreases in PI3K, pAkt following 24 h PAT exposure. Both trends were maintained in the presence of insulin (E,F) (* p < 0.05 relative to control).
Toxins 15 00244 g004
Toxins 15 00244 g005 550
Figure 5. PAT-modified GSK-3 activation corresponded with PI3K/Akt signaling trends while GLUT2 expression was widely compromised by PAT. Western blotting established PAT significantly increased GSK-3 inhibition by phosphorylation relative to total GSK-3 expression with no change GLUT2 in NG HEK293 (A) and NG HepG2 (C) cells. This was reversed in HG HEK293 (B) and HG HepG2 (D) cells with decreases in GLUT2, pGSK-3, and increased GSK-3 following 24 h PAT exposure. NG i+ cells (E) exposed to PAT showed no significant changes while HG trends were maintained in the presence of insulin (F) (* p < 0.05 relative to control).
Figure 5. PAT-modified GSK-3 activation corresponded with PI3K/Akt signaling trends while GLUT2 expression was widely compromised by PAT. Western blotting established PAT significantly increased GSK-3 inhibition by phosphorylation relative to total GSK-3 expression with no change GLUT2 in NG HEK293 (A) and NG HepG2 (C) cells. This was reversed in HG HEK293 (B) and HG HepG2 (D) cells with decreases in GLUT2, pGSK-3, and increased GSK-3 following 24 h PAT exposure. NG i+ cells (E) exposed to PAT showed no significant changes while HG trends were maintained in the presence of insulin (F) (* p < 0.05 relative to control).
Toxins 15 00244 g005
Toxins 15 00244 g006 550
Figure 6. PAT contributes to metabolic inflexibility by PDK-1 elevation and PDH inhibition under NG and HG conditions. Western blotting established PAT caused no significant differences in PDK-1, pPDH E1α and PDH E1α in NG HEK293 (A) and HG HEK293 (B) cells. PDK-1 was significantly increased with associated changed in pPDH E1α and PDH E1α in NG HepG2 (C), HG HepG2 (D) NG i+ HepG2 (E) and HG i+ HepG2 (F) cells following 24 h PAT exposure. (** p < 0.01, * p < 0.05 relative to control).
Figure 6. PAT contributes to metabolic inflexibility by PDK-1 elevation and PDH inhibition under NG and HG conditions. Western blotting established PAT caused no significant differences in PDK-1, pPDH E1α and PDH E1α in NG HEK293 (A) and HG HEK293 (B) cells. PDK-1 was significantly increased with associated changed in pPDH E1α and PDH E1α in NG HepG2 (C), HG HepG2 (D) NG i+ HepG2 (E) and HG i+ HepG2 (F) cells following 24 h PAT exposure. (** p < 0.01, * p < 0.05 relative to control).
Toxins 15 00244 g006
Table
Table 1. Extracellular lactate levels (mean ± SD) measured following 24 h PAT exposure in HepG2 and HEK293 cells.
Table 1. Extracellular lactate levels (mean ± SD) measured following 24 h PAT exposure in HepG2 and HEK293 cells.
TreatmentLactate Levels (mmol/L) Normoglycemic Media (NG)Lactate Levels (mmol/L) Hyperglycemic Media (HG)
HEK293 Control8.85 ± 0.130617.78 ± 0.07348
HEK293 0.2 μM PAT7.77 ± 0.179612.92 ± 0.1878
HEK293 2.0 μM PAT7.75 ± 0.310315.97 ± 0.1470
HepG2 Control3.36 ± 0.25315.58 ± 0.2368
HepG2 0.2 µM PAT2.64 ± 0.15515.35 ± 0.3101
HepG2 2.0 µM PAT3.12 ± 0.17965.17 ± 0.8410
HepG2 (i+) Control3.15 ± 0.13883.63 ± 0.07348
HepG2 (i+) 0.2 µM PAT2.79 ± 0.14703.69 ± 0.4736
HepG2 (i+) 2.0 µM PAT2.40 ± 0.048993.68 ± 0.2286
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Pillay, Y.; Nagiah, S.; Chuturgoon, A. Patulin Alters Insulin Signaling and Metabolic Flexibility in HepG2 and HEK293 Cells. Toxins 2023, 15, 244. https://doi.org/10.3390/toxins15040244

AMA Style

Pillay Y, Nagiah S, Chuturgoon A. Patulin Alters Insulin Signaling and Metabolic Flexibility in HepG2 and HEK293 Cells. Toxins. 2023; 15(4):244. https://doi.org/10.3390/toxins15040244

Chicago/Turabian Style

Pillay, Yashodani, Savania Nagiah, and Anil Chuturgoon. 2023. "Patulin Alters Insulin Signaling and Metabolic Flexibility in HepG2 and HEK293 Cells" Toxins 15, no. 4: 244. https://doi.org/10.3390/toxins15040244

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop